October 24, 2026
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Investors
Clinical Development Pipeline
Learn More
Quarterly Results
View Results
2025 Year in Review
View This Report
Key Ratios
Key Financial Ratios
Sustainability Report
Learn More
Latest Sustainability Developments
View Stories

Investor Email Alerts
Sign up to receive email alerts for various types of investor content.